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Abstract 
Background: Rhabdomyosarcoma is a rare malignant skeletal muscle tumor. It mainly occurs in children and young 
adults and has an unsatisfactory prognosis. Prior studies showed a direct myotoxic effect of bupivacaine on differenti-
ated muscle cells in vitro and in vivo. Exact mechanisms of this myotoxicity are still not fully understood, but a myo-
toxic effect on malignant muscle tumor cells has not been examined so far. Thus, the aim of this study was to examine 
if bupivacaine has cytotoxic effects on rhabdomyosarcoma cells, immortalized muscle cells and differentiated muscle 
cells.
Methods: Cell lines of rhabdomyosarcoma cells, immortalized muscle cells and differentiated muscle cells were 
established. After microscopic identification, cells were exposed to various concentrations of bupivacaine (500, 1,000, 
1,750, 2,500 and 5,000 ppm) for 1 and 2 h, respectively. 24 and 28 h after incubation the cultures were stained with 
propidium iodid and analyzed by flow cytometry. The fraction of dead cells was calculated for each experiment and 
the concentration with 50% cell survival (IC50) was computed. Cell groups as well as incubation and recovery time 
were compared (ANOVA/Bonferroni p < 0.01).
Results: The total number of cultured cells was similar for the different local anesthetics and examined concentra-
tions. Increasing concentrations of bupivacaine led to a decrease in survival of muscle cells. IC50 was highest for 
immortalized cells, followed by rhabdomyosarcoma cells and differentiated cells. Exposure time, but not recovery 
time, had an influence on survival.
Conclusion: Bupivacaine has clear but different cytotoxic effects on various muscle cell types in vitro. Differenti-
ated primary cells seem to be more vulnerable than tumor cells possibly because of more differentiated intracellular 
structures.
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Background
Rhabdomyosarcoma is a rare (4–7/1,000,000 children) 
and serious childhood cancer entity that arises from 
primitive muscle cells, the “rhabdomyoblasts”. The 
tumor cells fail to differentiate into adult striated muscle 
cells. These tumors account for about 5–8% of all child-
hood cancers, with a peak incidence in the age group of 
1–5  years. Overall, 50% of the children diagnosed with 
rhabdomyosarcoma survive 5  years. If possible radi-
cal resection and adjuvant radio-chemotherapy is per-
formed. Patients with metastatic disease have a poor 
prognosis because specific chemotherapeutic approaches 
are missing [1].
Myotoxic properties have been described for vari-
ous local anesthetics, with bupivacaine apparently being 
most myotoxic [2]. Exact mechanisms of the cytotoxic 
effect on skeletal muscle cells are still not entirely under-
stood. However, an involvement of intracellular calcium 
homeostasis has been shown to play an important role 
[3]. Local anesthetics (LA) increase intracellular calcium 
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levels by inducing sarcoplasmic release and simultane-
ously inhibiting calcium reuptake into the sarcoplasmic 
reticulum [3]. Furthermore inhibition of mitochondrial 
function with consecutively impaired cellular energy bal-
ance has also been described. Additionally to immediate 
necrosis of myocytes, certain LAs can induce apoptosis 
[3, 4]. Prior studies could show that apoptosis occurs 
within a few hours after treatment with local anesthetic. 
After 24  h mainly late apoptosis and necrosis can be 
found. At this stage cells can be identified by staining 
with propidium iodid (PI) [5].
The clinical effects of local anesthetic induced myo-
toxicity often remain unrecognized. The affected mus-
cle recovers within weeks after local anesthetic induced 
damage. Histological studies show that cell debris is 
rapidly removed. Damaged muscle cells are replaced by 
myoblasts that divide and form myotubes. Finally, the 
growing cells merge and differentiate into adult skeletal 
muscle fibers. To allow this recovery, undifferentiated 
myoblasts are suggested to be resistant to local anesthet-
ics. Rhabdomyosarcomas arise from undifferentiated 
myoblasts and might therefore also be resistant to local 
anesthetics.
Rapidly dividing cancer cells show numerous differ-
ences from differentiated cells of the same tissue type. 
In order to divide, the cell cycle is steadily repeated, with 
a concomitant doubling of macromolecular content. 
Rhabdomyosarcomas develop from myoblasts and fail to 
differentiate due to its rapid growth at the cost of differ-
entiation [6].
Commercially available immortalized cell lines are 
often used for experiments because they are easier to 
grow and often more robust to external stimuli. Mor-
phologically these cells are not different from the original 
tissue but functional modifications are possible. A sup-
pression of apoptotic pathways is often seen.
Myotoxic properties of bupivacaine on differentiated 
muscle cells as well as immortalized cells can be studied 
in cell cultures [4]. Rhabdomyosarcoma cells easily grow 
in vitro allowing the examination of potentially toxic sub-
stances [7].
Aim of this specific study was to investigate potential 
differences in cytotoxic effects of bupivacaine on rhabdo-
myosarcoma cells, immortalized muscle cells and differ-
entiated muscle cells in vitro.
Methods
Cell culture
Rhabdomyosarcoma cells (CLS-Cell Lines Service, Eppel-
heim, Germany), immortalized C2C12 (CLS-Cell Lines 
Service, Eppelheim, Germany) muscle cells and primary 
muscle cells were used for the study.
Cell line establishment
Cells were grown and differentiated as described earlier. 
[7] The C2C12 and the rhabdomyosarcoma cell line was 
grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(PAA Laboratories GmbH, Pasching, Austria) supple-
mented with 10% fetal bovine serum (Sigma-Aldrich 
Chemie GmbH, Taufkirchen, Germany) and l-glutamine 
2 mM (Life Technologies GmbH, Darmstadt, Germany).
The primary muscle cell culture was established with 
consent of the local committee for Laboratory Ani-
mal Care. Muscle cells of BALB/c AnNcrl mice were 
extracted, prepared and washed in phosphate buffered 
saline (PBS) (Sigma-Aldrich Chemie GmbH). Intact mus-
cles were incubated for 1.5 h with 8 mL 0.2% Collagenase 
Typ 1 (GIBCO® Cell Culture, Invitrogen GmbH, Darm-
stadt, Germany) in DMEM, 1% penicillinstreptomycin 
(Sigma-Aldrich Chemie GmbH) and 1% l-glutamine 
(Sigma-Aldrich Chemie GmbH) in Petri dishes (Sigma-
Aldrich Chemie GmbH). Skeletal muscles were carefully 
dissolved, and myofibers were separated. Intact single 
fibers were brought onto Matrigel and DMEM-coated 
6-well plates. After 3  min, 0.5  mL of plating medium 
(Table  1) was added. After 3  days, plating medium was 
replaced by proliferation medium (Table 1).
Having established a confluent monolayer in the cell 
lines after 3 days, medium was changed into differentia-
tion medium (Table 1) to force myoblasts to differentiate 
into myotubes (Fig. 1).
Cells were harvested with Trypsin–EDTA (Sigma-Aldrich 
Chemie GmbH) diluted 1:4 with PBS without calcium and 
magnesium chloride (Sigma-Aldrich Chemie GmbH).
Cell treatment
For the actual study cells were removed from the pri-
mary flask, counted and transferred to 6-well-plates 
Table 1 Different types of  medium for  primary skeletal 
muscle cell culture
Plating medium Dulbecco’s modified Eagle’s medium (DMEM)
10% horse serum (HS)
0.5% chick embryo extract (CEE)
1% penicillin–streptomycin (P/S)
1% l-glutamine
Proliferation medium DMEM
10% HS
10% fetal bovine serum (FBS)
1% CEE
1% P/S
1% l-glutamine
Differentiation medium DMEM
2% FBS
0.5% CEE
1% P/S
1% l-glutamine
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(neoLab Migge Laborbedarf-Vertriebs GmbH, Heidel-
berg, Germany) with approximately 150,000 cells per 
well. 72  h after dissemination, cells were treated with 
bupivacaine hydrochloride (Sigma-Aldrich Chemie 
GmbH, Taufkirchen, Germany) in concentrations of 0, 
500, 1,000, 1,750, 2,500 and 5,000 ppm. Every treatment 
was done in duplicate (two wells) at each of the three 
series. After incubation for 1 and 2  h bupivacaine was 
removed and cells were washed with PBS and cultured 
with growth medium, described above, for another 24 
and 48 h recovery time. Because evaluation was accom-
plished immediately after staining no fixation occurred. 
The cells from every harvest well were measured 
separately.
Cytotoxicty evaluation by flow cytometry
Necrotic cells without intact cell membrane were marked 
with PI (15  µM) (Invitrogen GmbH, Darmstadt, Ger-
many) and counted by flow cytometry (FACS Calibur, 
Becton–Dickinson, Heidelberg, Germany) The fraction of 
dead cells in relation to total number of cells was calcu-
lated by counting a total of 5,000 events per well.
Statistical analysis
For each cell type, incubation and recovery time the 
theoretical concentration with 50% cell survival (IC50) 
was calculated. For this pharmacodynamic modeling 
and analysis Phoenix™WinNonlin® 6.2 (Pharsight, Cer-
tara, St. Louis, MO, USA) was used. IC50 were com-
pared between cell types, incubation and recovery time 
using an ANOVA with Bonferroni correction with 
p  <  0.01 considered significant. Statistical analysis was 
accomplished with Microsoft Excel and IBM SPSS Sta-
tistics Version 19 (IBM Deutschland GmbH, Ehningen, 
Germany).
Results
Cell line identification
The growing cells could be identified microscopi-
cally according to morphological characteristics as 
rhabdomyosarcoma cells or differentiated muscle cells 
(Fig. 1).
Cell death measurement
Cell death was dose-dependently induced in primary 
muscle cells, immortalized muscle cells and rhabdomyo-
sarcoma cells. Results are given in Fig. 2.
Calculated IC50 values
Pharmacodynamic modeling showed different IC50 con-
centrations for the investigated cell lines, incubation and 
recovery periods (Table  2). The IC50 was highest for 
immortalized C2C12 cells followed by rhabdomyosar-
coma cells and differentiated primary muscle cells at the 
same incubation and recovery time.
For all cell types 2 hours incubation lead to more dead 
cells than incubation for one hour.
For a given cell type and incubation period recovery 
time did not influence the fraction of dead cells.
Combined results ignoring incubation and recov-
ery time showed a significantly different behavior of the 
examined cell lines. With more cell survival for immor-
talized cells, followed by rhabdomyosarcoma cells and 
primary muscle cells (Table 3).
Discussion
According to both in vitro and in vivo studies, local anes-
thetics have myotoxic properties. Various mechanisms of 
this myotoxicity are discussed. Local anesthetics influ-
ence the cellular calcium homeostasis, energy balance 
and liberate intracellular free radicals capable of induc-
ing apoptotic cascades. Prior investigations revealed that 
bupivacaine seems to be the most myotoxic local anes-
thetic of all clinically used substances [8].
Histological studies show a mixed picture of cell damage 
after exposure to bupivacaine. Morphologically sarcolemma 
membranes remain intact until total lysis and fragmenta-
tion of the fibers occurs. Vasculature, neural structures and 
connective tissue elements are visibly not affected in the 
examined sections [9]. Clinically, affected muscles rapidly 
Fig. 1 Microscopic images of a C2C12 cells; b primary muscle cells and c rhabdomyosarcoma cells.
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start to recover after exposure to myotoxic local anesthetics. 
Histological studies show that myoblasts start to divide and 
transform after elimination of cell debris. Growing myo-
tubes elongate and eventually merge into adult muscle cells 
[4]. Myoblasts as undifferentiated precursor cells therefore 
serve as an important reservoir for damage repair. To allow 
this form of recovery undifferentiated myoblasts have to be 
less vulnerable to anesthetic-induced damage.
The results of our in vitro study show that all examined 
cells are vulnerable to increasing concentrations of bupi-
vacaine. Primary differentiated muscle cells are more vul-
nerable than tumor cells and immortalized muscle cells.
Fig. 2 Fraction of living cells 24 and 48 h after incubation with increasing bupivacaine concentrations. Two different incubation periods are shown. 
Values are given as medians. 75% percentiles, minimum and maximum.
Table 2 Calculated bupivacaine concentration (ppm) with 50% cell survival (IC50)
Incubation/recovery  
time (h)
Differentiated primary muscle  
cells [IC50 ± SD] (ppm)
Rhabdomyosarcoma cells  
[IC50 ± SD] (ppm)
Immortalized C2C12 cells 
[IC50 ± SD] (ppm)
1/24 1,232 ± 421 2,400 ± 703 3,814 ± 1,104
1/48 1,472 ± 438 1,908 ± 658 3,436 ± 1,266
2/24 834 ± 300 1,958 ± 620 2,413 ± 840
2/48 1,132 ± 442 1,871 ± 598 2,526 ± 826
Table 3 Combined calculated IC50 bupivacaine concentrations (ppm) differentiating only cell type
ANOVA with Bonferroni * p < 0.01.
Incubation/recovery time  
combined (h)
Differentiated primary muscle cells 
[IC50 ± SD] (n = 24)
Rhabdomyosarcoma cells 
[IC50 ± SD] (n = 31)
Immortalized C2C12 
cells [IC50 ± SD] 
(n = 24)
1,161 ± 403* ppm 2,034 ± 584* ppm 3,297 ± 1,247* ppm
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An important difference between mature myocytes 
and myoblasts is the differentiation with highly specific 
calcium storage and release mechanisms. An impor-
tant mechanism of local anesthetic induced myotoxicity 
seems to be a pathological influence on the cellular cal-
cium homeostasis. An increased sarcoplasmic calcium 
release via the specific ryanodine receptor can be dem-
onstrated in vivo [6]. Local anesthetics also decrease the 
sarcoplasmic calcium reuptake by blocking the sarco-
plasmic calcium ATPase (SERCA) [3]. Due to the more 
developed calcium handling mechanisms differentiated 
myocytes are more vulnerable to local anesthetics.
Human rhabdomyosarcoma cells develop from myo-
blasts and fail to differentiate into adult muscle cells. The 
rapid growth is at the cost of differentiation [6]. Tumor 
cells are lacking a contractile apparatus with the accom-
panying calcium stores [3]. Calcium mediated myotoxic 
effects are therefore less likely in sarcoma cells. However 
this study shows that bupivacaine induces cell death in 
human rhabdomyosarcoma cells in vitro.
A possible explanation might be an affected cellular 
energy balance. Local anesthetics can influence cellular 
energy production by blocking mitochondrial function 
[10]. Sarcoma cells, similar to all fast growing tumor cells, 
have an increased energy demand. Compared to rest-
ing myoblasts sarcoma cells are rapidly dividing. This 
involves increased energy consumption [11]. An acute 
disruption of the cells mitochondrial energy supply could 
be compensated in a resting cell but not in cells with 
already increased energy demand. Any problem in the 
energy supply can lead to a complete breakdown of the 
cellular homeostasis.
Another possible pathway for bupivacaine induced 
toxic effects on sarcoma cells is the induction of apopto-
sis via activation of various caspases [12–14]. Immortal-
ized muscle cells are modified to evade apoptosis. This 
could explain why these cells seem to be more resistant 
to bupivacaine. Immortalized muscle cells morphologi-
cally look like differentiated muscle cells but function-
ally behave differently. A less developed calcium handling 
apparatus and suppressed apoptotic pathways make 
these cells less vulnerable to external stimuli. A behavior 
intended in commercially available cell lines.
As seen in prior laboratory and clinical studies incu-
bation time had an effect on cell survival. The longer the 
cells were exposed to with myotoxic substance, the more 
severe was the damage [7].
According to this study, recovery time had no effect 
on the fraction of cell survival. Surviving cells usually 
resume replication within hours and the amount of vital 
cells should increase with recovery time [11]. However, 
in the additional 24 h of recovery, cells did not multiply 
at rates seen without local anesthetic intoxication. The 
induced cytotoxic effects are apparently longer lasting 
than the actual incubation. Sustained inhibitory effects 
on cell replication or delayed cytotoxic mechanisms 
might be a possible explanation and need to be further 
investigated.
Conclusion
In vitro differentiated primary muscle cells are more vul-
nerable to bupivacaine than rhabdomyosarcoma cells 
and immortalized muscle cells. Exact mechanisms of this 
cytotoxicity are unknown and subject to further studies. 
Whether this described behavior is reproducible in vivo 
is subject to further research.
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